Navigation Links
Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
Date:9/3/2008

GAITHERSBURG, Md., Sept. 3 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. today announced the issuance of U.S. Patent Number 7,413,737 covering antibodies against human aspartyl (asparaginyl) beta-hydroxylase (HAAH), a proprietary human cancer biomarker and therapeutic target. These antibodies were developed in collaboration with the Massachusetts Institute of Technology (MIT) and Panacea has exclusive, worldwide rights to this patent for development of human cancer diagnostics and therapeutics. Panacea is developing PAN-622, an all-human sequence anti-HAAH monoclonal antibody covered under this patent, as a cancer therapeutic antibody drug and anticipates the start of Phase 1 clinical trials in early 2009.

HAAH is a cancer molecular marker that has been detected by immunohistochemical staining in a broad range of cancers; this marker was originally discovered at the Rhode Island Hospital / Brown University. Research done both at Panacea and in collaboration with Brown University / Rhode Island Hospital has established HAAH as an excellent drug target for cancer therapy as well as a marker for cancer diagnosis. HAAH over-expression has been observed in more than twenty different cancers, and HAAH has been shown to be highly specific for cancer and absent in adjacent non-affected tissue as well as tissue from cancer-free individuals. In cancer, HAAH is found on the cell surface and in normal cells found in minute quantities inside the cell. As such, HAAH is an excellent therapeutic target. Panacea has demonstrated the efficacy of PAN-622, an all-human sequence anti-HAAH monoclonal antibody, in animal models of cancer. In these experiments PAN-622 inhibited tumor growth in 90 percent of animals, with 40 percent showing no visible tumor. Tumors did not re-grow beyond the period of drug administration. Due to its all human sequence, PAN-622 is anticipated to have low toxicity in humans. And PAN-622 is currently being manufactured under cGMP at high yields.
'/>"/>

SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
2. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
3. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
4. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
5. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
8. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
9. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
10. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
11. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... MILPITAS, Calif. , July 10, 2014 ... a leader in advanced memory and analog IC solutions, ... call on Thursday, July 24, 2014, at 7:00 a.m. ... Company,s financial results for the fiscal 2014 third quarter ... conference call via telephone, dial 1-888-556-4997 before 6:50 a.m. ...
(Date:7/10/2014)... AMBLER, Pa. , July 10, 2014 /PRNewswire/ ... visited Moberg Research,s (Moberg) medical device manufacturing facility. ... how Moberg,s advanced neurological monitors facilitate cutting-edge research ... 2011, Rep. Kennedy and mental health advocate, ... non-profit organization dedicated to fostering fundamental changes that ...
(Date:7/10/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... completed the sale to Galderma of all rights to ... by Valeant for $1.4 billion in cash, pursuant to ... completed its acquisition of Galderma. "We ... to a company that is firmly committed to the ...
Breaking Medicine Technology:Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2
(Date:7/13/2014)... imaging device developed at Cedars-Sinai can provide early ... brain and are a classic sign of Alzheimer,s ... a clinical trial in Australia. , The researchers ... oral presentation at the Alzheimer,s Association International Conference ... by conference organizers to participate in a "breaking ...
(Date:7/13/2014)... Celebrity fitness trainer and former World Super ... with Aqua Health Labs for their flagship product PhytOriginal, ... The collaboration was recently announced live on ESPN Radio. ... actor, model, and a two time World Super Middleweight ... has prepared stars including Demi Moore, Hilary Swank and ...
(Date:7/13/2014)... Seattle, Wa (PRWEB) July 13, 2014 ... updated by Vkool.com, this is a comprehensive guide that ... to deal with KP (keratosis pilaris). This ...     Chapter 1: What Is Keratosis Pilaris? ,     Chapter ... Do I Know If I Have KP? , ...
(Date:7/12/2014)... NY (PRWEB) July 12, 2014 The ... growth over the past five years, buoyed by stable ... sector's supply management system. “Eggs are a relatively affordable ... per capita egg consumption generally grows in line with ... Analyst Will McKitterick. Furthermore, demand for new specialty egg ...
(Date:7/12/2014)... Dennis Thompson HealthDay ... There,s no way to guarantee that a surgical technique used ... incisions won,t increase the risk of spreading cancer to other ... The advisory panel to the Food and Drug Administration ... called laparoscopic power morcellation -- should sign a written consent ...
Breaking Medicine News(10 mins):Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Chicken Egg Production in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3
... innovative study to understand what factors may influence who contracts ... in the ethnic makeup of the disease, with the majority ... results of this paper, "HIV and Tuberculosis Co-infection Among Hispanics ... the February edition of the American Journal of Public ...
... have double the odds of dying before age 55, study ... are at a greater risk of dying young, a new ... likely to die before age 55 as are normal-weight children. ... leave behind young families, this poses a multigenerational, societal problem, ...
... explain osteoporosis among those with the eating disorder , WEDNESDAY, ... anorexia nervosa have excess levels of fat in their bone ... mainly young women, leads to extremely low body weight and ... that an emaciated young woman with almost no subcutaneous [below ...
... data from lower Manhattan residents suggest a link, nearly ... -- Nearly 10 years after the 9/11 attacks, residents ... World Trade Center site appear prone to persistent, sometimes ... preliminary," stressed study author Dr. Sara C. Crystal, an ...
... ... ... -- McLaren Software , a leader in asset information management solutions for Owner operators ... Forum in Orlando, Florida., , ,Due for release in March 2010, McLaren Services for Outlook ...
... of Ontario hospitals surveyed in a Queen,s University-led study do ... do exist have been tested. In addition, key players were ... preparedness was inadequate., "It,s not good enough just to have ... know how well it will work in an emergency," says ...
Cached Medicine News:Health News:Burden of HIV/TB infections increasingly falling on Hispanic community 2Health News:Premature Death Could Await Obese Kids 2Health News:Premature Death Could Await Obese Kids 3Health News:With Anorexia, Body May Hoard Fat in Bones 2Health News:Exposure to 9/11 Fumes Tied to Chronic Headaches 2Health News:Exposure to 9/11 Fumes Tied to Chronic Headaches 3Health News:McLaren Software Extends the Reach of Asset Document Management Processes 2
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: